Technology | October 27, 2008

New PET/CT Offers High Sensitivity, 'Motion Free' Technology

GE Healthcare is extending its Discovery product line with the introduction of the new Discovery PET/CT 600.

This system delivers the next evolution in PET/CT technologies, bringing powerful options to physicians to discover ways to detect disease early and manage with confidence. This new platform offers the scintillator with the high sensitivity, the next generation of MotionFree technology to capture detail and precision in areas subject to motion, plus enhanced workflow and fast reconstruction with the IBM BladeCenter.

This new addition to GE’s Discovery family of scanners continues GE’s commitment to help enable the earlier detection and monitoring of disease with advanced molecular imaging technology, in both hardware and software.

The new system will be optimized for use in oncology, which represents more than 90 percent of clinical PET/CT exams. The system continues using high-sensitivity crystals in the industry, along with GE’s exclusive VUE Point HD, High Definition imaging to help clinicians advance towards the goal of Motion Free PET/CT imaging. It reportedly has wide-view imaging for PET and CT and according to the manufacturer, has two to four times faster reconstruction.

Discovery Dimension's high-definition PET image processing for patient motion management and clinical productivity provide features that together address motion, which is one of the most significant factors in lesion characterization that degrade today’s PET/CT image quality. These technologies are continuously developed through the work of GE research and global clinical research partners in pursuit of motion free PET/CT imaging. The newest version of Discovery Dimension helps clinicians advance towards the goal of motion free PET/CT imaging by allowing the clinician to address imaging mismatches related to respiratory and cardiac motion. These include motion correction techniques that effectively improve clinical results and minimize blur caused by motion.

GE Healthcare is aslo showing a new application for PET image generation. This technology, called VUE Point, can help improve small lesion detectability, clinical confidence and exam productivity. Available on the Discovery Dimension with new installations or by ContinuumTM field upgrades for installed base Discovery ST systems, clinicians can perform advanced PET image generation to improve both qualitative and quantitative accuracy.

VUE Point incorporates advanced proprietary image reconstruction algorithms; including volume scatter correction and a patented image projection technique developed at GE’s Global Research facility, and is enabled by the Volume CT reconstruction technology development. VUE Point is applicable to both 2D and 3D PET acquisition modes, static, dynamic and motion imaging.

Related Content

SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Overlay Init